ReviewFrontiers in pharmacology2016
Impact of Cannabis, Cannabinoids, and Endocannabinoids in the Lungs.
Review in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 108 citations in OpenAlex.
- ACPA decreases non-small cell lung cancer line growth through Akt/PI3K and JNK pathways in vitro.Cell death & disease · 2021Trial
- Effect of vaporized Cannabidiol (CBD) on neuropathic pain and its potential implication for development of chronic lung inflammation in rats.Journal of cannabis research · 2026Article
- Alcohol and Cannabinoids Differentially Regulate Macrophage Polarization, with Co-Exposure Producing an Antagonistic Immunomodulatory Effect.International journal of molecular sciences · 2026Article
- Protective effect of cannabinoid type II receptor ligand on bleomycin-induced pulmonary fibrosis in mice.PloS one · 2026Article
- Is There a Place for Cannabinoids in Asthma Treatment?International journal of molecular sciences · 2025Review
- Effects of maternal edible THC consumption on offspring lung growth and function in a rhesus macaque model.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- Cannabinoids and alcohol co-exposure modulate pathogen-induced pulmonary immune responses.Frontiers in immunology · 2025Article
- Cannabis Use and Self-Reported Bothersome Symptoms in People with HIV.Cannabis (Albuquerque, N.M.) · 2025Article
- Therapeutic potential of agents targeting cannabinoid type 2 receptors in organ fibrosis.Pharmacology research & perspectives · 2024Review
- Alcohol activates cannabinoid receptor 1 and 2 in a model of pathogen induced pulmonary inflammation.Toxicology letters · 2024Article
- [Does medicinal cannabis or cannabis consumption have an influence on the perioperative anesthesiological management?]Die Anaesthesiologie · 2023Review
- Changes in frequency of cannabis use among people with HIV during the COVID-19 pandemic: a multi-methods study to explore the underlying reasons for change.The American journal of drug and alcohol abuse · 2023Article
- Differential inflammatory profile in the lungs of mice exposed to cannabis smoke with varying THC:CBD ratio.Archives of toxicology · 2023Article
- Modulation of pulmonary immune function by inhaled cannabis products and consequences for lung disease.Respiratory research · 2023Review
- The endocannabinoid system and breathing.Frontiers in neuroscience · 2023Review
- Discovery of a pyrano[2,3-b]pyridine derivative YX-2102 as a cannabinoid receptor 2 agonist for alleviating lung fibrosis.Journal of translational medicine · 2022Article
- Activation of cannabinoid-2 receptor protects against Pseudomonas aeruginosa induced acute lung injury and inflammation.Respiratory research · 2022Article
- Article
- Biomarkers of Airway Immune Homeostasis Differ Significantly with Generation of E-Cigarettes.American journal of respiratory and critical care medicine · 2022Article
- Marijuana Use and Health Outcomes in Persons Living With HIV: Protocol for the Marijuana Associated Planning and Long-term Effects (MAPLE) Longitudinal Cohort Study.JMIR research protocols · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the identification of cannabinoid receptors in the 1990s, a research field has been dedicated to exploring the role of the cannabinoid system in immunity and the inflammatory response in human tissues and animal models. Although the cannabinoid system is present and crucial in many human tissues, studying the impact of cannabinoids on the lungs is particularly relevant because of their contact with exogenous cannabinoids in the context of marijuana consumption. In the past two decades, the scientific community has gathered a large body of evidence supporting that the activation of the cannabinoid system alleviates pain and reduces inflammation. In the context of lung inflammation, exogenous and endogenous cannabinoids have shown therapeutic potential because of their inhibitory effects on immune cell recruitment and functions. On the other hand, cannabinoids were shown to be deleterious to lung function and to impact respiratory pathogen clearance. In this review, we present the existing data on the regulation of lung immunity and inflammation by phytocannabinoids, synthetic cannabinoids and endocannabinoids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.